Levels of minimal residual disease detected by quantitative molecular monitoring herald relapse in patients with multiple myeloma.

Abstract

MRD in patients with MM can be quantified reliably using TaqMan chemistry adapted to the LightCycler system. Residual tumor cell levels before transplantation as well as results of sequential molecular monitoring are predictive of relapse.